NXI Therapeutics, a Swiss-based specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, announced on Wednesday that it has named Dr Ruben Herrendorff as its new CEO and Dr Ulf Grawunder as its new director.

Dr Herrendorff has earlier served as co-founder and CEO of Polyneuron Pharmaceuticals AG. He is an experienced life sciences executive. He has been appointed to drive the next stage of its development.

Dr Ulf Grawunder is a serial biotech entrepreneur, who has founded and exited two biotech companies since 2004 that includes 4-Antibody (sold to US-based Agenus) and NBE-Therapeutics (sold to Boehringer Ingelheim). He has served as managing partner at Swiss Viopas Venture Consulting and co-founded T-CURX.